To understand why the connection matters, it helps to grasp both halves of the equation. m6A is added to RNA molecules by a suite of proteins called writers, spearheaded by the methyltransferase METTL3, which partners with METTL14 and auxiliary factors such as WTAP and VIRMA to deposit methyl groups onto thousands of transcripts. Two demethylases, FTO and ALKBH5, serve as erasers that strip the mark away, while a family of reader proteins, including YTHDF1, YTHDF2, YTHDC1 and the IGF2BP family, interprets the tag and decides the fate of the modified RNA, whether that means enhanced translation, accelerated degradation or altered splicing. The result is a dynamic, reversible layer of gene regulation that operates after DNA has been transcribed.

Ferroptosis, by contrast, is a violent and distinctive way to die. When iron accumulates inside a cell, it catalyses the Fenton reaction, converting hydrogen peroxide into hydroxyl radicals that shred the polyunsaturated fatty acids of cellular membranes. A self-amplifying lipid peroxidation cascade follows, rupturing the plasma membrane and shrivelling the mitochondria without ever activating the caspase enzymes that define apoptosis. Cells normally defend themselves through the cystine-glutathione-glutathione peroxidase 4 axis, in which the SLC7A11 transporter imports cystine to build the antioxidant glutathione, and through parallel systems involving FSP1, DHODH and the GCH1/BH4 pathway. Enzymes such as ACSL4 and LPCAT3, meanwhile, load vulnerable fatty acids into membranes and set the threshold at which the cascade ignites.

The new synthesis shows that m6A machinery grips this death circuitry at nearly every point. METTL3 marks the ACSL4 transcript in a YTHDC1-dependent manner, boosting production of the very enzyme that feeds lipid peroxidation. METTL16, working with the reader IGF2BP2, stabilises the SENP3 mRNA and thereby protects lactotransferrin from proteasomal destruction. On the eraser side, FTO lifts the antiferroptotic proteins GPX4, FTH1 and SLC7A11 while suppressing the iron importer TFR1, and ALKBH5 appears to stabilise ACSL4 mRNA. Among readers, IGF2BP3 binds specific motifs on GPX4 mRNA to tune antioxidant capacity, and hypoxia-driven long noncoding RNAs recruit YTHDF2 to degrade ACSL4 transcripts, forming feedback loops that respond to the tumour microenvironment.

What emerges from the disease-by-disease survey is a striking paradox. In aortic dissection, Parkinson’s disease and hepatic ischaemia-reperfusion injury, m6A-driven ferroptosis destroys healthy tissue and worsens disease; METTL3 suppresses SLC7A11 and FSP1 in the aorta, while YTHDF1 ramps up ACSL4 in dopaminergic neurons. Yet in gastric, lung and colorectal cancers, the very same mechanism becomes a weapon against the tumour, because forcing malignant cells into ferroptosis halts their growth. Even within a single tumour, the effect splits: ferroptosis in immune cells of the tumour microenvironment promotes cancer progression, while ferroptosis inside the cancer cells themselves suppresses it. Any therapy must therefore navigate this double-edged biology with precision.

The catalogue of specific axes is now long enough to guide drug design. In lung cancer, YTHDC1 stabilises FSP1 mRNA and restrains ferroptosis, and the JMJD6-METTL14-SLC3A2 axis drives carcinogenesis. In colorectal cancer, blocking AKT triggers ferroptosis through the FTO/YTHDF2/GPX4 pathway, and histone deacetylase inhibitors activate FTO and ALKBH5 to sensitise tumours. In bladder cancer, WTAP and YTHDF1 stabilise NRF2 mRNA and shield cells from lipid damage, while METTL7B marks ACSL3. In glioblastoma, the C5aR1-ERK pathway elevates METTL3 to protect GPX4, and in cervical cancer METTL14 destabilises FTH1 to enhance sorafenib-induced death. Cardiovascular studies implicate YTHDF2-mediated marking of NCOA4 in myocardial infarction and METTL14-driven ACSL4 modification in thoracic aneurysm, while in the kidney METTL3 modifies Hmox1 mRNA to trigger iron overload in acute injury.

Translational efforts are already following the map. The first-in-class METTL3 catalytic inhibitor STM2457 has shown prolonged survival in acute myeloid leukaemia models and, when paired with anti-PD-1 immunotherapy, can drive tumour regression in NAFLD-associated liver cancer. FTO inhibitors FB23 and FB23-2 suppress leukaemic proliferation, and the antibiotic mupirocin has been repurposed as an FTO inhibitor that pushes colorectal tumours into ferroptosis by cutting SLC7A11 and GPX4. Nanotechnology adds another layer: PLGA nanoparticles coated with gastric cancer cell membranes deliver STM2457 directly to tumours, and glutathione-bioimprinted nanocomposites simultaneously block FTO and deplete glutathione, inducing ferroptosis selectively in leukaemic blasts. Even a blood-brain-barrier-penetrating nanosystem carrying METTL3 inhibitors has shown benefit in mouse models of stroke and traumatic brain injury.

Nature’s own chemistry is joining the arsenal. Arbutin, an antioxidant from bearberry, eases fatty liver disease through the FTO/SLC7A11 pathway. Curdione from turmeric relatives promotes METTL14 and YTHDF2 while stripping away SLC7A11, SLC3A2 and GPX4 in colorectal cancer cells. Lobeline reverses lenvatinib resistance in liver cancer, chrysin covalently binds the enzyme ENO1 to recruit YTHDF2 against beta-catenin mRNA, and traditional formulations such as Yanghe Pingchuan granules relieve asthma by activating the METTL3/P53/SLC7A11 axis. Metformin, edaravone and interferon-alpha have all been drawn into the framework, each acting on m6A writers or readers to shift ferroptotic sensitivity in liver, brain and metabolic disease models.

The authors are candid that the field remains young. Most evidence comes from mouse models that may not translate cleanly to humans, the effect of m6A varies dramatically with cell type, tissue and disease stage, and current inhibitors of writers and erasers still suffer from off-target effects and incomplete selectivity. The conflicting roles of reader proteins remain unresolved, and the spatiotemporal dynamics of the m6A-ferroptosis network, particularly inside tumours and inflamed neural tissue, are only beginning to be charted. Future progress, the review argues, will depend on single-cell and spatial transcriptomics to map cellular heterogeneity, tissue-selective drug delivery, bifunctional molecules that hit both m6A effectors and ferroptosis nodes, and biomarkers such as YTHDF1/NRF2 and FTO/GPX4 for patient stratification. If those hurdles fall, the humble methyl tag on RNA may become one of the most powerful levers in medicine, a switch that doctors could flip to kill tumours, protect the heart and rescue dying neurons.

Subject of Research: Regulation of ferroptosis by N6-methyladenosine RNA methylation and its therapeutic implications

Article Title: m6A methylation in ferroptosis regulation: mechanisms, targets, and therapeutic interventions

Article References: Wen, C., Jiao, Y., Wang, Z., Shi, T., Wang, Y., Xu, J., Deng, T., Zhang, G., & Xiao, C. (2026). m6A methylation in ferroptosis regulation: mechanisms, targets, and therapeutic interventions. Journal of Advanced Research, 88, 825-840. https://doi.org/10.1016/j.jare.2026.01.021

Image Credits: AI Generated

DOI: 10.1016/j.jare.2026.01.021

Keywords: m6A methylation, ferroptosis, RNA modification, METTL3, FTO, GPX4, SLC7A11, cancer therapy, lipid peroxidation, nanoparticle drug delivery, programmed cell death, epitranscriptomics